News

TC-5619 is a highly selective alpha7 neuronal nicotinic receptor modulator, which is subject to licence by Targacept’s strategic partner AstraZeneca. In the trial, TC-5619 met the primary efficacy

The Phase 1/2 trial is an open-label study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and clinical activity of BMN 701. In the study, BMN 701 will

In its CRL, the FDA has showed its concern regarding the use of the in-vitro performance data and clinical pharmacology data to bridge MannKind‘s next generation inhaler to

The new plant will include 8,000 liters of production capacity, a complete purification installation, and ample room for additional future capacity expansions. Commercial approvals for the new site

TransferCenter version 2.1 also features a fresh user interface for easier navigation, specific protocols by case type to help transfer personnel reduce errors, and aids to make data

PharmaVigilant claims that the I-Warehouse 3.0 offers immediate and ubiquitous access to study data with comparable results. I-Warehouse offers search criteria and a more streamlined selection process with

A positive opinion by the COMP immediately precedes official designation of darinaparsin as an orphan drug by the European Commission (EC). Ziopharm expects to commence a registration-directed study

Clinical trials of Ceplene showed that it prolongs remission and prevents relapse in patients under the age 60, and it was also successful in averting additional 20% of

The model will be used to get a better understanding of the benefits of weight loss against the long-term risks of cardiovascular outcomes in patients treated with weight